Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fenoterol→

Fenoterol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
13392-18-2
Molecular formula
C17H21NO4
Molecular weight
303.35 g/mol
Drug class
Short-acting beta-2 adrenergic receptor agonistbronchodilator
Mechanism of action
Activates beta-2 adrenergic receptors on bronchial smooth muscle, increases intracellular cyclic AMP and produces bronchodilation. At higher systemic exposure, beta-adrenergic effects may also influence cardiac rate and contractility.
Indications / reported uses
  • Relief of reversible bronchospasm in asthma and other obstructive airway diseases in countries where fenoterol inhalers remain authorised
  • Some formulations have historically been used for obstetric tocolysis; route-specific indications must not be transferred to inhaled products
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Fenoterol Environmental Risk Assessment (ERA) (the Fenoterol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.